Core Viewpoint - Via Biotech (01873) experienced a significant stock increase of over 18%, closing at 2.35 HKD with a trading volume of 64.71 million HKD, following the successful hosting of the Viva Biotech Innovation Forum 2026 during the J.P. Morgan Healthcare Conference, which focused on advancements in artificial intelligence and new drug types [1][1][1] Group 1: Company Developments - The company showcased its advancements in AI-enabled peptide drug development and the CRDMO platform during the forum, highlighting the acceleration of AI integration in key research and industrialization processes [1][1] - The positive outlook from Zheshang Securities indicates that the increasing proportion of AI application projects in the CRO sector and the rollout of significant commercial projects in CDMO will sustain the company's high profitability trend [1][1] - Guosheng Securities believes that the company's synergistic development of CRO and CDMO, along with AI-driven efficiency improvements and investment incubation ecosystem construction, positions it to benefit from the rising global innovation drug industry, leading to steady performance growth and long-term value release [1][1]
港股异动 | 维亚生物(01873)尾盘涨超18% AI驱动研发提效及投资孵化生态构建